Invenia Insights

Invenia Insights

Welcome to Invenia Insights!

This is the first of our monthly newsletters, where we aim to deliver valuable insights from the life science, medtech and biopharma markets, straight to your inbox. Throughout October, our team produced an array of industry content that we think is worth sharing:


MedTech & HealthTech


Global Director Tanya Ridding looked into the fastest-growing sectors for HealthTech UK VC:

  • UK HealthTech startups have raised over $2.3B in VC funding so far in 2024 & Q3 saw almost $1B in Healthtech VC funding – the highest investment in any UK sector this quarter.
  • 50% of UK-based “Unicorns” in 2024 so far operate in the Healthtech space (including, IntraBio Inc and ElevenLabs).
  • The UK has emerged as the undisputed leader in European Femtech - attracting $652.9M of VC funding since 2019 – more than Germany, Belgium, and France combined during these 5 years.
  • Femtech startup Flo Health Inc. raised $200M in Q3, marking the largest UK VC deal of the quarter and the 4th largest Femtech round ever globally.
  • UK VCs are on track to raise a record $12.2B in additional dr powder by the end of the year, surpassing the previous record of $11.5B raised in 2021 during the height of the pandemic boom years. Across all sectors, UK VC has raised over $12.4B in 2024, almost as much as France and Germany combined.

Tanya also showcased some exciting updates we’ve seen throughout this year in the field of surgical robotics:

  • Globus Medical faced FDA warning letter over surgical robotics platform
  • Intuitive received 510k clearance and launched DaVinci5
  • KARL STORZ is set to acquire Asensus Surgical
  • 美敦力 began new clinical studies to expand Hugo surgical robot indications
  • Medrobotics Corporation put surgical robotics assets up for sale amid Chapter 7 bankruptcy
  • Mendaera, Inc. . purchased Avail Medsystems technology and raised $73M in Series B funding
  • Johnson & Johnson was ordered to pay $1B in damages in Auris shareholder suit
  • Sony announced its development of a microsurgery assistance robot
  • Stryker expands Mako with My Mako collaboration with Apple and plans for Mako Shoulder & Mako Spine in H2
  • THINK Surgical inks collaborations for TMINI including Zimmer Biomet, Maxx Orthopaedics Inc., b-ONE Ortho, Corp. & Signature Orthopaedics

Tanya brought to the forefront the importance of gender diversity in MedTech leadership:

The industry's push toward gender parity in leadership has made only modest progress in recent years, with improvements in representation plateauing. Despite early momentum, it is clear that women remain underrepresented in senior roles across major companies. Medical Design & Outsourcing compared the executive leadership composition across the 100 top MedTech companies worldwide and found the following:

  • As of 2024, women occupy just 24.4% of executive positions, a very slight increase from 23.6% in 2023 despite the increased awareness as to the importance of closing the gap Leaders of the pack in terms of female executive leadership include: Ambu (????%), Getinge (????.??%) and Insulet (????.??%)
  • Meanwhile, 3 companies, Demant, Medacta International and Alphatec Spine reported NO women in top executive leadership roles
  • >??% of the Top 100 had female CEOs
  • ????% of entry-level positions in the industry are held by females, further highlighting the disparities in leadership representation

Given the scarcity of female candidates for top roles, executive search firms with expertise in gender diversity can play a pivotal role. These partners can not only identify qualified female candidates but also help companies create a more inclusive hiring process, ensuring that biases are addressed, and women are given equitable opportunities.

Earlier this year, Tanya produced a blog piece on women in the industry and strategies for change, you can read it here: https://www.inveniagroup.com/blog/women-medtech-leadership-strategy/ ?


Life Sciences

?

Headhunter Katie Davis held a spotlight on Cerillo – a company committed to advancing scientific discovery through the development of cutting-edge tools for cellular and microbial research.

What makes them unique?

Their platform supports microbial research across academic, government, and industrial labs, facilitating early discoveries to high-throughput screening. Its compact, portable design enhances data collection, standardization, and analysis, providing accessible and affordable solutions for comprehensive biological insights. To shine a light on these early-stage companies to demonstrate their unique product offerings to enough scientists who could use their technology, Katie aims to produce this Spotlight series every month.

Katie’s monthly biotech updates produced an array of industry news from the month of September.

In this newsletter, you can find exciting collaborations, product updates, acquisitions, legal updates and so much more. Take a look here: https://www.dhirubhai.net/newsletters/7159634236071669760/

Katie also produced her monthly funding round update, diving into September’s funding throughout the biotech industry.

Throughout the month, there was over $14 billion raised by companies in the biotech and biopharma space - over double what was raised in August. Take a look here: https://www.inveniagroup.com/blog/september-biotech-funding/

Managing Consultant Revna C?mertpay showcased a variety of exciting fundings throughout the life science industry this month, to name a few:

  • Avenue Biosciences raised $2.5m to transform protein production in biotech with AI-enhanced tech
  • Aura Biosciences CEO Sells $300,838 in Stock Amid Positive Clinical Developments
  • Tolerance Bio has just announced the completion of a $17.2 million seed financing round to advance its groundbreaking thymus-based therapies.
  • Cytovale , a pioneering company in early detection technologies, has successfully secured $100 million in Series D funding, led by Sands Capital. This investment will accelerate the expansion of their groundbreaking diagnostic tool, IntelliSep, which is the first FDA-cleared cellular host diagnostic specifically indicated for use in emergency departments (ED).
  • Sequentia Biotech Secures €10M Equity Investment to Accelerate Omics Innovation
  • C2N Diagnostics s has been awarded over $7 million by the Alzheimer's Drug Discovery Foundation’s Diagnostics Accelerator to advance its novel biomarker platform.


Are you a life science leader looking to succeed with a new startup?

While there are no precise failure rate figures for life science startups, in general, 25% of businesses fail within their first year and 65% of businesses fail within ten years.

So, if you’re thinking about starting a business or you’ve recently made the leap, how can you optimize your chances of success? In this blog piece, we offer tips and tricks for your success. Whether it be the importance of self-awareness, making those tough decisions, communication, creating that positive work environment or pre-empting failure, we offer top ticks for avoiding startup failure: https://www.inveniagroup.com/blog/succeeding-business-leaders-life-science/


Recently published success stories:


Building a high-impact speciality brands team for a global pharmaceutical manufacturer: In 2019, we partnered with one of the fastest-growing global pharmaceutical companies in Europe, to assist with hires for their generic drugs team, successfully placing multiple professionals over our five-year partnership.

Following success across the generics team, in 2022, the client came to us to help hire for the launch of their first NCE which resulted in placing a team of individuals over the next couple of years who would be working towards the strategic development of the speciality brands division.

You can read the full case study over on our blog, here: https://www.inveniagroup.com/blog/building-speciality-brands-team-pharmaceuticals/


Hiring the first Director of Scientific Affairs for a long-standing partner: An industry global leader and established partner of over 10 years got in touch with us to assist in growing their sales and commercial team across the US. The company required a Director of Scientific Affairs for the East Coast US. This would be a brand-new function, requiring the individual to amplify brand awareness and develop relationships with industry leaders.

Our team embarked upon a proactive search strategy. Leveraging our extensive network and industry expertise, we immediately identified several potential candidates who met the company’s criteria.

You can read the full case study on our blog, here: https://www.inveniagroup.com/blog/case-study-hiring-director-scientific-affairs-east-coast-us/


Looking to partner with an executive search company like ours? Whatever the size of the business or seniority of the candidate our aim is simple; to ensure our clients build great teams and our candidates secure jobs they love. If you’re a startup looking for talent, or you’d like to learn more about our recruitment services, submit your vacancy here, and a recruitment consultant who specialises in your field will be in touch shortly.

Or, are you an expert looking for your next career opportunity? Here are just some of the roles we’re recruiting for right now:

  • Director of Scientific Affairs (Life Sciences) – West Coast, US
  • Quality Coordinator (Life Sciences) – Namur, Belgium
  • Account Manager (Life Sciences) – Belgium
  • Field Service Engineer (Life Sciences) – Belgium
  • Spine Sales Representative (Medical devices) – US
  • Senior Account Manager (Life Sciences) – Germany
  • Territory Account Manager (Life Sciences) – Germany
  • QMS Manager (Biopharma) – London, UK
  • Senior Account Manager (Life Sciences) – San Francisco, US
  • Account Executive (Life sciences) – DACH




www.inveniagroup.com

要查看或添加评论,请登录